Drugs /

gvax pancreatic cancer vaccine

Back to Drugs List

Overview

NCI Definition [1]:
An irradiated, autologous pancreatic cancer vaccine consisting of patient-specific pancreatic cancer cells genetically modified to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF), with potential immunostimulating and antineoplastic activities. Upon vaccination, GVAX pancreatic cancer vaccine secretes GM-CSF. In turn, GM-CSF may stimulate the body's immune system against tumor cells by enhancing the activation of dendritic cells (DCs) and promoting antigen presentation to both B- and T-cells. In addition, GM-CSF promotes antibody-dependent cellular cytotoxicity (ADCC), and increases interleukin-2-mediated lymphokine-activated killer cell function.

Clinical Trials

View Clinical Trials for gvax pancreatic cancer vaccine

Gvax pancreatic cancer vaccine has been investigated in 7 clinical trials, of which 7 are open and 0 are closed. Of the trials investigating gvax pancreatic cancer vaccine, 1 is early phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open).

Pancreatic adenocarcinoma and pancreatic ductal adenocarcinoma are the most common diseases being investigated in gvax pancreatic cancer vaccine clinical trials [2].

Drug Details

Synonyms [2]:
gm-csf gene transduced allogeneic pancreatic cancer vaccine
NCIT ID [1]:
C91707

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.